Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand

Stock Track

Mar 03

BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.

The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.

Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1139657449"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139657449\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139657449?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139657449","market":"nz","top_or_hot":-1,"title":"Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand","media":"Stock Track","content":"<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeOne Medicines Plummets 5.34% Intraday Amid Valuation Concerns Following Rebrand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-03 22:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.</p><p>The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.</p><p>Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ONC","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1139657449","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139657449","pubTimestamp":1772549849,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ONC":"百济神州"},"translate_title":"个股追踪|品牌重塑后估值担忧BeOne Medicines盘中暴跌5.34%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1},"content_text":"BeOne Medicines (ONC) shares fell sharply by 5.34% during intraday trading on Tuesday, continuing a recent trend of weakness for the oncology-focused biopharmaceutical company.The decline follows the company's rebrand from BeiGene to BeOne Medicines in May 2025, which has been accompanied by sustained share price pressure. Analysis suggests the stock may be facing valuation uncertainty, trading at $314.36 compared to some fair value estimates of $404.19, while also carrying a high P/E multiple of 121.5x.Investor concerns appear centered on the company's heavy reliance on its BRUKINSA therapy and potential risks from late-stage trial disappointments, despite strong revenue growth of 41% year-over-year in the second quarter. The market seems to be questioning whether current prices adequately reflect future growth prospects amid these uncertainties.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}